Perrigo Company plc (0Y5E.L)
USD 26.0
(-2.11%)
USD 26.0
(-2.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 1.68 Billion USD | 15.46% |
| 2022 | 1.45 Billion USD | 2.77% |
| 2021 | 1.41 Billion USD | -21.98% |
| 2020 | 1.81 Billion USD | 2.36% |
| 2019 | 1.77 Billion USD | -3.18% |
| 2018 | 1.83 Billion USD | -7.48% |
| 2017 | 1.97 Billion USD | -3.52% |
| 2016 | 2.05 Billion USD | 19.82% |
| 2015 | 1.71 Billion USD | 18.28% |
| 2014 | 1.44 Billion USD | 13.1% |
| 2013 | 1.28 Billion USD | 16.83% |
| 2012 | 1.09 Billion USD | 15.95% |
| 2011 | 944.87 Million USD | 26.66% |
| 2010 | 746.01 Million USD | 25.17% |
| 2009 | 595.99 Million USD | 8.17% |
| 2008 | 550.96 Million USD | 37.18% |
| 2007 | 401.62 Million USD | 0.98% |
| 2006 | 397.74 Million USD | 52.75% |
| 2005 | 260.38 Million USD | -2.83% |
| 2004 | 267.96 Million USD | 16.55% |
| 2003 | 229.91 Million USD | 8.5% |
| 2002 | 211.9 Million USD | 14.86% |
| 2001 | 184.49 Million USD | 3.95% |
| 2000 | 177.48 Million USD | -14.18% |
| 1999 | 206.8 Million USD | -20.83% |
| 1998 | 261.2 Million USD | 1.44% |
| 1997 | 257.5 Million USD | 11.71% |
| 1996 | 230.5 Million USD | 4.54% |
| 1995 | 220.5 Million USD | 3.42% |
| 1994 | 213.2 Million USD | 17.99% |
| 1993 | 180.7 Million USD | 37.73% |
| 1992 | 131.2 Million USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q1 | 358.1 Million USD | -16.19% |
| 2024 Q2 | 395 Million USD | 10.3% |
| 2023 Q4 | 427.3 Million USD | 3.92% |
| 2023 Q2 | 428 Million USD | 3.43% |
| 2023 Q1 | 413.8 Million USD | 8.15% |
| 2023 FY | 1.68 Billion USD | 15.46% |
| 2023 Q3 | 411.2 Million USD | -3.93% |
| 2022 Q1 | 337.8 Million USD | -6.79% |
| 2022 FY | 1.45 Billion USD | 2.77% |
| 2022 Q3 | 362.9 Million USD | -2.47% |
| 2022 Q4 | 382.6 Million USD | 5.43% |
| 2022 Q2 | 372.1 Million USD | 10.15% |
| 2021 Q3 | 336.4 Million USD | -3.61% |
| 2021 FY | 1.41 Billion USD | -21.98% |
| 2021 Q1 | 368.4 Million USD | -21.48% |
| 2021 Q2 | 349 Million USD | -5.27% |
| 2021 Q4 | 362.4 Million USD | 7.73% |
| 2020 Q1 | 483.2 Million USD | 0.5% |
| 2020 Q4 | 469.2 Million USD | 9.6% |
| 2020 Q3 | 428.1 Million USD | -1.52% |
| 2020 FY | 1.81 Billion USD | 2.36% |
| 2020 Q2 | 434.7 Million USD | -10.04% |
| 2019 FY | 1.77 Billion USD | -3.18% |
| 2019 Q3 | 412.8 Million USD | -4.18% |
| 2019 Q4 | 480.8 Million USD | 16.47% |
| 2019 Q1 | 448.8 Million USD | 1.31% |
| 2019 Q2 | 430.8 Million USD | -4.01% |
| 2018 Q4 | 443 Million USD | 4.28% |
| 2018 FY | 1.83 Billion USD | -7.48% |
| 2018 Q2 | 471 Million USD | -4.4% |
| 2018 Q1 | 492.7 Million USD | -3.92% |
| 2018 Q3 | 424.8 Million USD | -9.81% |
| 2017 Q1 | 464.4 Million USD | 1.98% |
| 2017 Q2 | 504.6 Million USD | 8.66% |
| 2017 Q3 | 497.8 Million USD | -1.35% |
| 2017 Q4 | 512.8 Million USD | 3.01% |
| 2017 FY | 1.97 Billion USD | -3.52% |
| 2016 Q4 | 455.4 Million USD | -10.05% |
| 2016 FY | 2.05 Billion USD | 19.82% |
| 2016 Q2 | 567.2 Million USD | 8.47% |
| 2016 Q1 | 522.9 Million USD | -6.51% |
| 2016 Q3 | 506.3 Million USD | -10.74% |
| 2015 Q1 | 378.8 Million USD | -1.3% |
| 2015 Q4 | 559.3 Million USD | 1.91% |
| 2015 FY | 1.71 Billion USD | 18.28% |
| 2015 Q2 | 628.1 Million USD | 65.81% |
| 2015 Q3 | 548.8 Million USD | -12.63% |
| 2014 Q3 | 321.8 Million USD | -22.61% |
| 2014 FY | 1.44 Billion USD | 13.1% |
| 2014 Q1 | 315 Million USD | -12.67% |
| 2014 Q2 | 415.8 Million USD | 32.0% |
| 2014 Q4 | 383.8 Million USD | 19.27% |
| 2013 Q3 | 356.3 Million USD | 0.03% |
| 2013 Q4 | 360.7 Million USD | 1.23% |
| 2013 Q1 | 331.36 Million USD | 7.88% |
| 2013 FY | 1.28 Billion USD | 16.83% |
| 2013 Q2 | 356.2 Million USD | 7.5% |
| 2012 FY | 1.09 Billion USD | 15.95% |
| 2012 Q3 | 285.26 Million USD | -2.93% |
| 2012 Q2 | 293.87 Million USD | 5.23% |
| 2012 Q1 | 279.27 Million USD | -5.29% |
| 2012 Q4 | 307.16 Million USD | 7.68% |
| 2011 Q1 | 239.08 Million USD | -4.18% |
| 2011 FY | 944.87 Million USD | 26.66% |
| 2011 Q4 | 294.87 Million USD | 29.57% |
| 2011 Q3 | 227.57 Million USD | -6.09% |
| 2011 Q2 | 242.33 Million USD | 1.36% |
| 2010 Q3 | 213.95 Million USD | 7.4% |
| 2010 Q4 | 249.5 Million USD | 16.61% |
| 2010 Q1 | 185.86 Million USD | -5.63% |
| 2010 Q2 | 199.21 Million USD | 7.18% |
| 2010 FY | 746.01 Million USD | 25.17% |
| 2009 Q1 | 149.59 Million USD | -3.05% |
| 2009 Q3 | 163.99 Million USD | 0.09% |
| 2009 Q4 | 196.94 Million USD | 20.09% |
| 2009 FY | 595.99 Million USD | 8.17% |
| 2009 Q2 | 163.85 Million USD | 9.53% |
| 2008 Q4 | 154.3 Million USD | 7.0% |
| 2008 Q1 | 157.94 Million USD | 21.11% |
| 2008 Q2 | 144.93 Million USD | -8.24% |
| 2008 Q3 | 144.21 Million USD | -0.5% |
| 2008 FY | 550.96 Million USD | 37.18% |
| 2007 Q4 | 130.41 Million USD | 11.73% |
| 2007 FY | 401.62 Million USD | 0.98% |
| 2007 Q1 | 100.2 Million USD | 1.92% |
| 2007 Q3 | 116.71 Million USD | 7.6% |
| 2007 Q2 | 108.47 Million USD | 8.25% |
| 2006 FY | 397.74 Million USD | 52.75% |
| 2006 Q4 | 98.32 Million USD | 3.92% |
| 2006 Q3 | 94.61 Million USD | -12.37% |
| 2006 Q2 | 107.97 Million USD | 11.0% |
| 2006 Q1 | 97.27 Million USD | -7.85% |
| 2005 Q2 | 65.65 Million USD | 4.29% |
| 2005 FY | 260.38 Million USD | -2.83% |
| 2005 Q4 | 105.57 Million USD | 21.46% |
| 2005 Q3 | 86.91 Million USD | 32.37% |
| 2005 Q1 | 62.96 Million USD | -6.11% |
| 2004 Q2 | 69.45 Million USD | 4.23% |
| 2004 Q1 | 66.63 Million USD | -9.83% |
| 2004 FY | 267.96 Million USD | 16.55% |
| 2004 Q4 | 67.05 Million USD | 3.62% |
| 2004 Q3 | 64.71 Million USD | -6.82% |
| 2003 Q1 | 58.7 Million USD | -8.69% |
| 2003 Q4 | 73.89 Million USD | 27.44% |
| 2003 Q2 | 45.23 Million USD | -22.96% |
| 2003 Q3 | 57.98 Million USD | 28.2% |
| 2003 FY | 229.91 Million USD | 8.5% |
| 2002 Q3 | 61.67 Million USD | 38.29% |
| 2002 Q1 | 55.15 Million USD | -9.95% |
| 2002 FY | 211.9 Million USD | 14.86% |
| 2002 Q4 | 64.29 Million USD | 4.24% |
| 2002 Q2 | 44.6 Million USD | -19.14% |
| 2001 Q4 | 61.25 Million USD | 20.37% |
| 2001 Q1 | 53.77 Million USD | -6.78% |
| 2001 FY | 184.49 Million USD | 3.95% |
| 2001 Q2 | 19.92 Million USD | -62.95% |
| 2001 Q3 | 50.88 Million USD | 155.45% |
| 2000 Q1 | 36.79 Million USD | -31.86% |
| 2000 FY | 177.48 Million USD | -14.18% |
| 2000 Q3 | 53.11 Million USD | 111.93% |
| 2000 Q2 | 25.06 Million USD | -31.89% |
| 2000 Q4 | 57.68 Million USD | 8.6% |
| 1999 Q3 | 55.6 Million USD | 29.6% |
| 1999 FY | 206.8 Million USD | -20.83% |
| 1999 Q1 | 62.7 Million USD | 3.98% |
| 1999 Q2 | 42.9 Million USD | -31.58% |
| 1999 Q4 | 54 Million USD | -2.88% |
| 1998 Q4 | 60.3 Million USD | 47.43% |
| 1998 FY | 261.2 Million USD | 1.44% |
| 1998 Q2 | 56.7 Million USD | -11.27% |
| 1998 Q1 | 63.9 Million USD | -13.41% |
| 1998 Q3 | 40.9 Million USD | -27.87% |
| 1997 FY | 257.5 Million USD | 11.71% |
| 1997 Q3 | 66.8 Million USD | 11.33% |
| 1997 Q2 | 60 Million USD | -7.98% |
| 1997 Q1 | 65.2 Million USD | -6.72% |
| 1997 Q4 | 73.8 Million USD | 10.48% |
| 1996 Q3 | 62.6 Million USD | -9.67% |
| 1996 Q2 | 69.3 Million USD | 19.07% |
| 1996 Q1 | 58.2 Million USD | -4.9% |
| 1996 FY | 230.5 Million USD | 4.54% |
| 1996 Q4 | 69.9 Million USD | 11.66% |
| 1995 FY | 220.5 Million USD | 3.42% |
| 1995 Q3 | 61.9 Million USD | 21.85% |
| 1995 Q2 | 50.8 Million USD | -6.62% |
| 1995 Q4 | 61.2 Million USD | -1.13% |
| 1995 Q1 | 54.4 Million USD | -0.91% |
| 1994 Q4 | 54.9 Million USD | -8.35% |
| 1994 FY | 213.2 Million USD | 17.99% |
| 1994 Q3 | 59.9 Million USD | 20.77% |
| 1994 Q1 | 53.2 Million USD | -3.97% |
| 1994 Q2 | 49.6 Million USD | -6.77% |
| 1993 FY | 180.7 Million USD | 37.73% |
| 1993 Q1 | 45 Million USD | 0.67% |
| 1993 Q2 | 46 Million USD | 2.22% |
| 1993 Q3 | 54.8 Million USD | 19.13% |
| 1993 Q4 | 55.4 Million USD | 1.09% |
| 1992 Q4 | 44.7 Million USD | -0.67% |
| 1992 Q1 | 36.6 Million USD | 22.82% |
| 1992 Q2 | 36.3 Million USD | -0.82% |
| 1992 Q3 | 45 Million USD | 23.97% |
| 1992 FY | 131.2 Million USD | 0.0% |
| 1991 Q4 | 29.8 Million USD | -65.79% |
| 1991 Q3 | 87.1 Million USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Editas Medicine, Inc. | -99.52 Million USD | 1788.369% |
| Dynavax Technologies Corporation | 182.11 Million USD | -822.704% |
| Supernus Pharmaceuticals, Inc. | 523.74 Million USD | -220.845% |
| Illumina, Inc. | 2.74 Billion USD | 38.761% |
| Thermo Fisher Scientific Inc. | 15.22 Billion USD | 88.962% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 17666.381% |
| Walgreens Boots Alliance, Inc. | 26.52 Billion USD | 93.665% |
| IQVIA Holdings Inc. | 5.23 Billion USD | 67.925% |
| Heron Therapeutics, Inc. | 10.04 Million USD | -16633.718% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 85.131% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 8630.382% |
| Waters Corporation | 1.76 Billion USD | 4.587% |
| Biogen Inc. | 7.3 Billion USD | 76.988% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 3807.446% |
| Evolus, Inc. | 140.52 Million USD | -1095.793% |
| Adicet Bio, Inc. | -6.09 Million USD | 27656.576% |
| Cara Therapeutics, Inc. | 14.79 Million USD | -11258.659% |
| bluebird bio, Inc. | -4.03 Million USD | 41797.27% |
| Esperion Therapeutics, Inc. | 73.06 Million USD | -2199.807% |
| FibroGen, Inc. | 128.9 Million USD | -1203.606% |
| Agilent Technologies, Inc. | 3.46 Billion USD | 51.504% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 5491.486% |
| Homology Medicines, Inc. | -7.22 Million USD | 23345.262% |
| Geron Corporation | -123.5 Million USD | 1460.615% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | -10.707% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | -364.16% |
| Myriad Genetics, Inc. | 476.4 Million USD | -252.729% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 575579.452% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 521.37% |
| Zoetis Inc. | 5.83 Billion USD | 71.196% |
| Abeona Therapeutics Inc. | 302 Thousand USD | -556323.841% |
| Mettler-Toledo International Inc. | 2.16 Billion USD | 22.529% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 11.761% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 80.476% |
| Kala Pharmaceuticals, Inc. | -303 Thousand USD | 554687.459% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | -115.847% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 536969.01% |
| Verastem, Inc. | -62 Thousand USD | 2710422.581% |
| Nektar Therapeutics | 53.47 Million USD | -3042.227% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | -587.182% |
| Aclaris Therapeutics, Inc. | -85.21 Million USD | 2071.93% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | -53.743% |
| OPKO Health, Inc. | 318.12 Million USD | -428.217% |
| Exelixis, Inc. | 1.75 Billion USD | 4.396% |
| Neurocrine Biosciences, Inc. | 1.84 Billion USD | 9.04% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | -253.104% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| uniQure N.V. | 2.21 Million USD | -75764.56% |
| Imunon, Inc. | -720 Thousand USD | 233487.268% |
| Blueprint Medicines Corporation | 236.58 Million USD | -610.276% |
| Insmed Incorporated | 239.63 Million USD | -601.233% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | -163.844% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | -9602.639% |
| TG Therapeutics, Inc. | 219.1 Million USD | -666.928% |
| Incyte Corporation | 3.44 Billion USD | 51.16% |
| Emergent BioSolutions Inc. | 343.9 Million USD | -388.63% |